Citations

Clear

128 citation(s) found for "Nathan, Foster".

Abstract 5092: Participant satisfaction with cancer chemoprevention clinical trials: The Mayo Clinic Cancer Prevention Network (CPN) experience
Zahrieh, David M. , Foster, Nathan R. , Mandrekar, Sumithra J. , McMurray, Ryan P. , Limburg, Paul J.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 5092-5092

10.1158/1538-7445.am2019-5092 Get It

Abstract INTRODUCTION Participating in a clinical trial is a personal choice and an individual experience. Several barriers to recruitment of high risk men and women in chemoprevention trials have been documented; however, to our knowledge, there are no existing reports on participant satisfaction in such trials. Therefore, our aim was to describe and evaluate participants’ perception of their experience with participating in chemoprevention trials conducted by CPN by summarizing the 5-item “Was It Worth It” (WIWI) tool for each trial and across the trials, and according to race/ethnicity, sex, age, site, and organ of primary interest. METHODS Because participants who participate in chemoprevention trials tend to be at increased cancer-risk, but otherwise healthy, the WIWI tool can help answer simple questions about participants’ assessment of whether or not participation in such a trial was worthwhile. The WIWI tool was consistently administered at the end of the intervention period in each trial conducted by CPN; since 2003, 7 trials have completed the study intervention period and are included in the results reported here. RESULTS The scientific focus of the 7 trials targeted 5 organs: breast, colorectum, esophageal, hepatobiliary, and lung. Of the 485 participants registered to these 7 trials, 419 (86.4%) were non-Hispanic white, 19 (3.9%) non-Hispanic black, 32 (6.6%) Hispanic, 14 (2.9%) other race/ethnicity, and 1 (0.2%) unknown race/ethnicity; there were 120 (24.7%) females. In total, 446 (92.0%) participants completed the WIWI questionnaire at the end of their respective intervention period. Across the trials, 93% [95% CI] [90.6%, 95.4%] of the participants indicated that participation was worthwhile and 92% [89.5%, 94.5%] reported that they would participate again. Additionally, 414 (92.8%) participants indicated that they would recommend participating in the current research study to others, while 10 (2.3%) indicated that they would not and 22 (4.9%) were uncertain. Furthermore, several participants provided actionable feedback to the question “If there was one thing that could have been done to improve your experience in this research study, what would it be?” Participant feedback on overall changes in quality of life and on their expectations with participation in the trial was positive but more nuanced, varying according to trial and participant composition. CONCLUSION In this dataset of chemoprevention trial participants enrolled through the CPN consortium, highly favorable feedback was evident with respect to the overall study experience, suggesting that the recruitment and retention methods employed are facilitating success. These data can be used to help advance the NCI accrual quality improvement program in developing/enhancing strategies to improve accrual, retention, and adherence as well as enhance participant diversity in subsequent trials. Citation Format: David Zahrieh, Ryan P. McMurray, Nathan R. Foster, Paul J. Limburg, Sumithra J. Mandrekar. Participant satisfaction with cancer chemoprevention clinical trials: The Mayo Clinic Cancer Prevention Network (CPN) experience [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5092.
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell Carcinoma
Price, Katharine A. , Moore, Eric J. , Patel, Samir H. , Hinni, Michael L., García, Joaquín J. , Graner, Darlene E., Foster, Nathan R. , Ginos, Brenda, Neben-Wittich, M.A. , Garces, Yolanda I. , Chintakuntlawar, Ashish V. , Olsen, Kerry D., Abel, Kathryn M. Van , Kasperbauer, Jan L. , Janus, Jeffrey R. , Waddle, Mark R. , Miller, Robert C. , Shiraishi, Satomi , Foote, Robert L. , Neben-Wittich, Michelle, Waddle, Mark, Van Abel, Kathryn M , Chintakuntlawar, Ashish V , Daniel, J. , Price, Daniel L. , Shiraishi, Satomi

Mayo Clinic

Journal of Clinical Oncology | June 4, 2019 | Volume: 37 | Issue: 22 | Pages: 1909-1918

10.1200/jco.19.00463 | PMID 31163012 Get It

PURPOSE The purpose of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma could maintain historical rates for disease control while reducing toxicity and preserving swallow function and quality of life (QOL). PATIENTS AND METHODS MC1273 was a single-arm phase II trial testing an aggressive course of RT de-escalation after surgery. Eligibility criteria included patients with p16-positive oropharyngeal squamous cell carcinoma, smoking history of 10 pack-years or less, and negative margins. Cohort A (intermediate risk) received 30 Gy delivered in 1.5-Gy fractions twice per day over 2 weeks along with 15 mg/m 2 docetaxel once per week. Cohort B included patients with extranodal extension who received the same treatment plus a simultaneous integrated boost to nodal levels with extranodal extension to 36 Gy in 1.8-Gy fractions twice per day. The primary end point was locoregional tumor control at 2 years. Secondary end points included 2-year progression-free survival, overall survival, toxicity, swallow function, and patient-reported QOL. RESULTS Accrual was from September 2013 to June 2016 (N = 80; cohort A, n = 37; cohort B, n = 43). Median follow-up was 36 months, with a minimum follow-up of 25 months. The 2-year locoregional tumor control rate was 96.2%, with progression-free survival of 91.1% and overall survival of 98.7%. Rates of grade 3 or worse toxicity at pre-RT and 1 and 2 years post-RT were 2.5%, 0%, and 0%. Swallowing function improved slightly between pre-RT and 12 months post-RT, with one patient requiring temporary feeding tube placement. CONCLUSION Aggressive RT de-escalation resulted in locoregional tumor control rates comparable to historical controls, low toxicity, and little decrement in swallowing function or QOL.
Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.
Foster, Nathan R. , Zoroufy, Alexander J., Price, Katharine A. , Kang, Hyunseok , Sherman, Eric J. , Morton, Roscoe F., Katabi, Nora , Kang, Hyunseok , Ho, Alan L. , Worden, Francis P. , Adkins, Douglas R. , Bowles, Daniel W. , Burtness, Barbara , Münster, Pamela N. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 6020-6020

10.1200/jco.2019.37.15_suppl.6020 Get It

6020 Background: A subset of salivary gland cancer (SGCs) express the androgen receptor (AR). This phase II trial evaluated the anti-androgen enzalumatide (Astellas) for patients with AR+ SGCs. Methods: Locally advanced/unresectable or metastatic AR+ SGCs were enrolled (AR status was centrally confirmed). Prior therapy with AR-targeted drugs was allowed. Enzalutamide 160 mg orally once daily was given (1 cycle= 28 days). The primary endpoint was confirmed response (RR) according to RECIST v1.1 within the first 8 cycles. Secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety. A Simon-Optimal two-stage design was used to detect a 20% RR (vs. 5%) (alpha = 5%; beta = 90%). > 1 response(s) in the first 21 would trigger accrual to 41; > 4 responses would be considered promising. Results: 46 eligible patients (pts) were enrolled (40 M, 6 F; median age 65) in 22 months. In the first 21 pts, we initially had 2 confirmed PRs allowing for full study accrual, though one was later changed to stable disease. Among the 46 pts, 7 had PR as best response, though only 2 were confirmed within the first 8 cycles (4% (95% CI: 0.5-15%). Two other PRs did not count towards the primary endpoint due to 1) development beyond 8 cycles (cycles 12-18) and 2) a confirmatory scan completed <4 weeks apart. The other 3 pts with unconfirmed PR developed progression of disease (PD) after the first PR scan. 24 pts had stable disease; 15 pts PD as best response. Among 11 pts previously treated with AR-targeted therapy, best responses were 1 confirmed PR, 7 SD, 3 PD. With a median follow-up of 11.7 months (mo), OS at 12 mo was 66% (95% CI: 52-83%), PFS at 12 mo was 24% (95% CI: 14-42%), and median PFS was 5.5 mo (95% CI: 3.7-7.3). Conclusions: This is the first prospective trial evaluating an antiandrogen alone for AR+ SGCs. The failure to meet the protocol-defined measure of success was due in part to the lack of durability of initial responses. The clinical activity observed suggests the AR-dependence of AR+ SGCs, even among those previously treated with other hormonal therapies. Support: U10CA180821, U10CA180882; Astellas; https://acknowledgments.alliancefound.org. Clinical trial information: NCT02749903.
Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers.
Colón‐Otero, Gerardo , Weroha, S. John , Zanfagnin, Valentina , Foster, Nathan R. , Asmus, Erik, Hendrickson, Andrea E. Wahner , Jatoi, Aminah , Block, Matthew S. , Dinh, Tri, Robertson, Matthew , Camoriano, John , Butler, Kristina , Copland, John A. , Langstraat, Carrie , Glaser, Gretchen

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 5510-5510

10.1200/jco.2019.37.15_suppl.5510 Get It

5510 Background: Single agent aromatase inhibitor (AI) therapy is associated with limited clinical activity in ovarian cancer (OC) and endometrial cancers (EC). AI therapy was associated with a progression free survival (PFS) at 12 weeks of only 20% in relapsed OC (Bowman et al, 2002) and a median PFS of 1 month in relapsed EC (Rose et al, 2000). In Estrogen Receptor (ER) positive metastatic breast cancer, clinical studies had shown a significant prolongation of PFS with the addition of the cyclin kinase 4/6 inhibitor ribociclib to AI (Hortobagyi et al, 2016). Here, we report the results of a phase 2 clinical trial of the combination of ribociclib and letrozole in patients with relapsed ER positive OC or EC. Objectives: Primary endpoint was the proportion of patients with relapsed ER positive OC or EC alive and progression-free after 12 weeks of therapy (PFS12) with the combination of ribociclib given at a dose of 400 mg orally daily and letrozole 2.5 mg orally daily. A PFS of 45% was considered a favorable result based on the data referenced above from Bowman et al. Methods: Eligibility criteria included patients with relapsed ER positive OC or EC, with measurable disease, not previously treated with ribociclib or AIs. Xenografts were created from CT guided tumor biopsies at baseline to assess feasibility. Results: A total of 40 patients were enrolled (20 with OC and 20 with EC) ) with a median age of 61 years (range: 30-82) and 64.5 (range: 52-75) in the OC and EC groups respectively. Among the OC patients, 17 had high grade serous carcinomas and 3 had low grade serous carcinomas. 11 EC patients had endometrioid cancers (3 with grade 1 tumors) and 9 had high grade serous tumors. Ten out of 20 OC patients and 11/20 EC patients were alive and progression-free at 12 weeks (PFS12 of 50 and 55%, respectively). The most common grade 3 or higher adverse events (occurring in at least 5 pts) were leukopenia (18%), lymphopenia (18%), neutropenia (13%), and fatigue (13%). 34 tumor biopsies were suitable for injection into mice and 44% engrafted. ER expression persisted through multiple passages in mice. Two of three EC PDX models exhibited improved PFS with letrozole/ribociclib compared to letrozole alone. Conclusions: The combination of ribociclib and letrozole is associated with a promising 50% and 55% PFS12 in patients with ER positive relapsed OC or EC respectively. Creation of xenograft tumor models from CT guided biopsies of OC and EC tumors was feasible. Clinical trial information: NCT02657928.
Alliance A091104: A phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma.
Foster, Nathan R. , Meyers, Jeffrey P., Vasudeva, Shyamprasad Deraje, Katabi, Nora , Pfister, David G. , Horvath, Laura E., Erlichman, Charles , Ho, Alan L. , Antonescu, Cristina R. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 6039-6039

10.1200/jco.2015.33.15_suppl.6039 Get It

Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).
Kulke, Matthew H. , Niedzwiecki, Donna , Foster, Nathan R. , Fruth, Briant, Kunz, Pamela L. , Kennecke, Hagen F. , Wolin, Edward M. , Niedzwiecki, Donna , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4005-4005

10.1200/jco.2015.33.15_suppl.4005 Get It

Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).
Wilcox, Ryan Eldredge, Foster, Nathan R. , Meyers, Jeffrey P., Goldberg, Richard M. , Nair, Suresh , Shields, Anthony F. , Chan, Emily , Kahlenberg, Morton S., Shi, Qian , Sinicrope, Frank A. , Sargent, Daniel J. , Gill, Sharlene , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3590-3590

10.1200/jco.2015.33.15_suppl.3590 Get It

Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance).
Foster, Nathan R. , Grothey, Axel, Chan, Emily , Shields, Anthony F. , Goldberg, Richard M. , Kahlenberg, Morton S., Singh, Preet Paul , Shi, Qian , Nair, Suresh, Gill, Sharlene , Sinicrope, Frank A. , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3531-3531

10.1200/jco.2015.33.15_suppl.3531 Get It

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
Hálfdánarson, Þorvarður R. , Foster, Nathan R. , Kim, George P., Meyers, Jeffrey P., Smyrk, Thomas C. , McCullough, Ann E. , Ames, Matthew M. , Jaffe, Jeffrry P., Halfdanarson, Thorvardur R , Alberts, Steven R.

Mayo Clinic

The Oncologist | January 24, 2019 | Volume: 24 | Issue: 5 | Pages: 589-e160

10.1634/theoncologist.2018-0878 | PMID 30679315 Get It

Abstract Lessons Learned Dual epidermal growth factor receptor (EGFR)-directed therapy with erlotinib and panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the clinical relevance is uncertain given the limited role of gemcitabine monotherapy. A significantly longer overall survival was observed in patients receiving the dual EGFR-directed therapy. The dual EGFR-directed therapy resulted in increased toxicity. Background Gemcitabine is active in patients with advanced pancreatic adenocarcinoma. The combination of erlotinib, an oral epidermal growth factor receptor (EGFR) inhibitor, and gemcitabine was shown to modestly prolong overall survival when compared with gemcitabine alone. The North Central Cancer Treatment Group (now part of Alliance for Clinical Trials in Oncology) trial N064B compared gemcitabine plus erlotinib versus gemcitabine plus combined EGFR inhibition with erlotinib and panitumumab. Methods Eligible patients with metastatic adenocarcinoma of the pancreas were randomized to either gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle with erlotinib 100 mg p.o. daily (Arm A) or the same combination with the addition of panitumumab 4 mg/kg on days 1 and 15 of a 28-day cycle (Arm B). The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, the confirmed response rate, and toxicity. Comparison between arms for the primary endpoint was done with a one-sided log-rank test, and a p value less than .20 was considered statistically significant. Response rate comparison was done with Fisher's exact test. All other reported p values are two-sided. Results A total of 92 patients were randomized, 46 to each arm. The median overall survival was 4.2 months in Arm A and 8.3 months in Arm B (hazard ratio, 0.817; 95% confidence interval [CI], 0.530–1.260; p = .1792). The progression-free survival was 2.0 months in Arm A and 3.6 months in Arm B (hazard ratio, 0.843; 95% CI, 0.555–1.280; p = .4190). A partial confirmed response was seen in 8.7% of patients on Arm A and 6.5% on Arm B (p = .9999). No patients had a complete response. Grade 3 and higher nonhematologic toxicities were more common in patients on Arm B compared with those on Arm A (82.6% vs. 52.2%; p = .0018). Conclusion Dual EGFR-directed therapy resulted in a significant prolongation of overall survival in patients with advanced adenocarcinoma of the pancreas but was associated with substantially increased toxicities. Dual EGFR-directed therapy in combination with gemcitabine alone cannot be recommended for further study, as single-agent gemcitabine is no longer considered an appropriate therapy for otherwise fit patients with metastatic pancreatic cancer.
Trial in progress: A multicenter phase II study of pembrolizumab in patients with advanced small bowel adenocarcinomas.
Overman, Michael J. , Foster, Nathan R. , Kim, Sunnie S., Murphy, Janet E., Höchster, Howard S. , Hálfdánarson, Þorvarður R. , Welch, Jack, Halfdanarson, Thorvardur R , Pedersen, Katrina S. , Bekaii‐Saab, Tanios , Boland, Patrick M. , Wilson, Richard H. , McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: TPS535-TPS535

10.1200/jco.2018.36.4_suppl.tps535 Get It

TPS535 Background: Small bowel adenocarcinoma (SBA) is a rare malignancy, possibly because of the high rate of immunosurveillance in baseline small bowel function, and is frequently diagnosed in late stages. Due to these factors, there is no consistent standard of care for metastatic disease beyond first-line where several prospective studies have confirmed activity of FOLFOX/CAPOX. Historically, second-line treatment of SBA has been extrapolated from colon/gastric cancer. Recent studies suggest that SBA has a distinct genomic profile, including higher incidence of microsatellite instability, compared to gastric and colon cancers. Additionally, the tumor microenvironment reflects a greater degree of PD-L1 expression and infiltration by lymphocytes. Immune checkpoint inhibitors have not previously been tested in SBA unselected for MSI status. Methods: The study is a phase 2, multicenter, single-arm clinical trial of pembrolizumab (200 mg IV every 3 weeks) for patients with unresectable or metastatic SBA refractory to first-line chemotherapy. Forty patients with any tumor mismatch repair status will be enrolled at 8 US sites as part of the ACCRU network and International Rare Cancer Initiative (IRCI) with a primary objective to assess the confirmed response rate (H0 p < 10%, HA: p > 30%) to pembrolizumab. Secondary endpoints include PFS, OS, and adverse events. Correlative aims include assessing blood and tissue biomarkers (i.e. PD-L1, MSI-H/MSS status, cfDNA, mutation burden, etc.) for association with clinical benefit. An interim analysis will be performed to assess efficacy after 18 patients become evaluable. The study is open with 16 patients enrolled at time of submission. Clinical trial information: NCT02949219.